(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
5 days till quarter result
(bmo 2024-05-10)
Expected move: +/- 7.89%
@ $17.42
发出时间: 10 Feb 2024 @ 02:49
回报率: 40.78%
上一信号: Feb 9 - 00:44
上一信号:
回报率: 5.05 %
Live Chart Being Loaded With Signals
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies...
Stats | |
---|---|
今日成交量 | 57 799.00 |
平均成交量 | 114 722 |
市值 | 369.90M |
EPS | $0 ( 2024-03-13 ) |
下一个收益日期 | ( $-1.200 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.400 |
ATR14 | $0.129 (0.53%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-12 | Mahal Jeetinder Singh | Buy | 900 | Voting Common Stock |
2024-03-12 | Mahal Jeetinder Singh | Sell | 900 | Voting Common Stock |
2024-03-12 | Mahal Jeetinder Singh | Buy | 900 | Stock Option (right to buy) |
2024-02-15 | Martell Ron | Buy | 100 000 | Stock Option (right to buy) |
2024-02-15 | Mahal Jeetinder Singh | Buy | 40 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
91.95 |
Last 82 transactions |
Buy: 17 940 158 | Sell: 1 631 987 |
音量 相关性
Jasper Therapeutics, Inc. 相关性 - 货币/商品
Jasper Therapeutics, Inc. 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-1.11M (0.00 %) |
EPS: | $-6.18 |
FY | 2023 |
营收: | $0 |
毛利润: | $-1.11M (0.00 %) |
EPS: | $-6.18 |
FY | 2022 |
营收: | $0 |
毛利润: | $-1.31M (0.00 %) |
EPS: | $-6.63 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.69 |
Financial Reports:
No articles found.
Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。